Role of anti-domain 1-ß2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: reply

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 10, 2016, Pages 2078-2080

  De Craemer, A S ^a   Devreese, K M J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN; PHOSPHOLIPID ANTIBODY;

ANALYTIC METHOD; ANTIBODY TITER; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; CHEMILUMINESCENCE IMMUNOASSAY; DIAGNOSTIC VALUE; ETHNICITY; GEOGRAPHY; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; GLYCOPROTEINS; HUMANS;

EID: 84984806978     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13428     Document Type: Letter

References (10)

1. Zhang S, Wu Z, Chen S, Li J, Wen X, Li L, Zhang W, Zhao J, Zhang F, Li Y. Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci Rep 2016; 6: 23839.
2. 2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost 2016; 14: 1779–87.
3. 2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; 13: 782–7.
4. 2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767–73.
5. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012; 12: 313–17.
6. Pelkmans L, Kelchtermans H, de Groot PG, Zuily S, Regnault V, Wahl D, Pengo V, de Laat B. Variability in exposure of epitope G40-R43 of domain I in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS ONE 2013; 8: e71402.
7. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540–5.
8. Devreese K, Kelchtermans H, de Laat B. Differences in sensitivity of two automated panels for anticardiolipin and anti-β2 glycoprotein antibodies in the laboratory diagnosis of antiphospholipid syndrome due to the exposure of the domain I epitope of β2glycoprotein I on the solid phase [abstract]. J Thromb Haemost 2014; 12: LA06.
9. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 792–5.
10. Devreese KM, Van Hoecke F. Anticardiolipin and anti-beta2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays. Thromb Res 2011; 128: 598–600.